In 4Q17, Novartis’s (NVS) subsidiary Alcon generated revenues of $1.56 billion compared to $1.44 billion in 4Q16, which reflected ~8% growth on a year-over-year (or YoY) basis and ~2% growth quarter-over-quarter.
In 3Q17, JNJ vision care generated revenues of $1.1 billion, which reflected a ~48% YoY (year-over-year) rise and a 3% QoQ (quarter-over-quarter) rise.
Novartis (NVS) has focused its efforts on improving its customer service levels and entering into lucrative partnering deals to boost profitability for its Alcon business.
The MFS Massachusetts Investors Growth Stock Fund – Class A (MIGFX) is the only fund in this review that has outperformed the passively managed SPDR S&P 500 ETF Trust (SPY).
